EPISODE · Jul 2, 2021 · 15 MIN
Coronapod: the biomarker that could change COVID vaccines
from Nature Podcast
Since the beginning oft he pandemic, researchers have searched for a biomarker which indicates immune protection from COVID-19 known as a correlate of protection. Now, the team developing the Oxford–AstraZeneca COVID-19 vaccine have published the first results of their so-called 'breakthrough study' which indicated puts forwards thresholds of neutralising antibodies that they suggest correlate with protection. The hope is that, should these results be confirmed, such biomarkers could speed up the development of new vaccines, and provide better ways to monitor the efficacy of tweaked vaccine aimed at fighting variants.News: Scientists identify long-sought marker for COVID vaccine successSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
Since the beginning oft he pandemic, researchers have searched for a biomarker which indicates immune protection from COVID-19 known as a correlate of protection. Now, the team developing the Oxford–AstraZeneca COVID-19 vaccine have published the first results of their so-called 'breakthrough study' which indicated puts forwards thresholds of neutralising antibodies that they suggest correlate with protection. The hope is that, should these results be confirmed, such biomarkers could speed up the development of new vaccines, and provide better ways to monitor the efficacy of tweaked vaccine aimed at fighting variants.News: Scientists identify long-sought marker for COVID vaccine successSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Coronapod: the biomarker that could change COVID vaccines
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m